VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogene‐driven non‐small‐cell lung cancers

Molecular agents targeting the epidermal growth factor receptor (EGFR)‐, anaplastic lymphoma kinase (ALK)‐ or c‐ros oncogene 1 (ROS1) alterations have revolutionized the treatment of oncogene‐driven non‐small‐cell lung cancer (NSCLC). However, the emergence of acquired resistance remains a significa...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Sci
Main Authors: Watanabe, Hiromi, Ichihara, Eiki, Kayatani, Hiroe, Makimoto, Go, Ninomiya, Kiichiro, Nishii, Kazuya, Higo, Hisao, Ando, Chihiro, Okawa, Sachi, Nakasuka, Takamasa, Kano, Hirohisa, Hara, Naofumi, Hirabae, Atsuko, Kato, Yuka, Ninomiya, Takashi, Kubo, Toshio, Rai, Kammei, Ohashi, Kadoaki, Hotta, Katsuyuki, Tabata, Masahiro, Maeda, Yoshinobu, Kiura, Katsuyuki
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2021
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8088971/
https://ncbi.nlm.nih.gov/pubmed/33410241
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.14801
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados